Results Announced from Phase 2 Trial of MIS416 in Secondary Progressive MS Suggest No Benefit

SUMMARY Top-line results of a one-year, phase 2 clinical trial of MIS416 in secondary progressive MS have been announced by the study’s sponsor, Innate Immunotherapeutics Limited.

  • None of the clinical or MRI measures suggested benefit of MIS416 over placebo.
  • The company announced plans to continue analyzing the results for safety and benefits, and to determine whether its compassionate use program, which makes MIS416 available to some people with secondary progressive MS in Australia, will continue.
DETAILS Background: MIS416 is a naturally occurring agent derived from bacteria that can…

Favicon of da :

Prosegui la lettura...
Traduci l'articolo...

Sclerosi Multipla News

Potrebbe interessarti anche

Argomenti correlati